Skip to content

Clinical trials

Anemia, Refractory, with Excess of Blasts trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Anemia, Refractory, with Excess of Blasts Phase: Not applicable Clear all

22 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20021
20032
20041
20071
20081
20121
20133
20141
20161
20201
20211
20221
20231
20252
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed10
Recruiting6
Terminated5
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Masonic Cancer Center, University of Minnesota2
University of California, San Francisco2
University of Washington2
Advice Pharma Group srl1
Asan Medical Center1
Case Comprehensive Cancer Center1
Children's Hospital of Philadelphia1
European Institute of Oncology1
Fred Hutchinson Cancer Center1
Fujian Medical University Union Hospital1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Anemia, Refractory, with Excess of Blasts22
Leukemia, Myeloid, Acute17
Precursor Cell Lymphoblastic Leukemia-Lymphoma11
Leukemia10
Hodgkin Disease8
Lymphoma, Mantle-Cell8
Lymphoma, Non-Hodgkin8
Multiple Myeloma8
Burkitt Lymphoma7
Congenital Abnormalities7

Trials

Showing 51 to 22 of 22. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.